Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Sponsor: Regeneron Pharmaceuticals

Expanded Access
Sponsor score: 60

ClinicalTrials ID:NCT06132191

This program provides expanded access to cemiplimab for patients with solid tumors through Individual Patient IND applications. Availability is location-dependent. Cemiplimab, the intervention, is a drug offered under compassionate use requests. Eligibility criteria are not specified in the provided information.

Patient Parameters

Program Overview

Provide expanded access of cemiplimab in patients with solid tumors

Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Eligibility Criteria

Get This Program In Your Inbox

You can sign up and apply your patients for this program.